The Globe and Mail reports in its Thursday, Nov. 16, edition that Desjardins Securities analyst Jerome Dubreuil has reaffirmed his "hold" recommendation for Well Health Technologies. The Globe's David Leeder writes that Mr. Dubreuil gave his share target a 25-cent trim to $5.25. Analysts on average target the shares at $7.96. Mr. Dubreuil says in a note: "Well Health Technologies reported results which were slightly ahead of expectations. The company also provided 2024 revenue guidance which slightly beat consensus. However, profitability growth is lagging top-line improvement and management appears to be tilting capital allocation toward primary care. Although attractive consolidation opportunities exist in this segment, we believe these operations are not as scalable as pure technology, and therefore we do not think the 13 times EV/2024 EBITDA is particularly attractive." The Globe reported on Aug. 4, 2022, that Mr. Dubreuil was worried about "mounting recessionary concerns and rising rates" for companies like Well Health, which he rated "hold." It was then worth $3.67. The Globe reported on Nov. 12, 2022, that Mr. Dubreuil had reiterated his "hold" call for Well Health when it was worth $3.12.